Sat.Apr 19, 2025 - Fri.Apr 25, 2025

article thumbnail

Email Marketing Campaigns: A Valuable Tactic in Pharma Marketing

Pharma Marketing Network

Introduction In the ever-evolving world of healthcare promotion, pharma brands are constantly seeking reliable, cost-effective, and targeted strategies to stay connected with healthcare professionals (HCPs) and patients. Enter email marketing campaigns a digital tactic that’s proving to be more than just effective. But are these campaigns truly worth the investment in 2025’s competitive and compliance-heavy landscape?

HIPAA 52
article thumbnail

STAT+: Eli Lilly opens a new legal front in its battle against compounded GLP-1s

STAT

Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their affiliates, but is using a new line of attack — the drugmaker accused two of the companies of engaging in the corporate practice of medicine. To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genetic breakthroughs could point pharma to a long COVID drug

PharmaVoice

The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

342
342
article thumbnail

Antibody treatment demonstrates potential in lupus kidney disease

European Pharmaceutical Review

New Phase III data has demonstrated the potential benefit of the monoclonal antibody obinutuzumab to treat lupus nephritis. This therapy is already approved for B cell malignancies. The REGENCY Phase III clinical trial evaluated 271 adults with active lupus nephritis, a severe complication of lupus that inhibits kidney function. Participants were randomised to receive either obinutuzumab plus mycophenolate mofetil and glucocorticoids as standard therapy, or a placebo plus standard therapy.

111
111
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Pharma and healthcare deals in Q1 2025 remain stable amid shift to scalable global models

Express Pharma

Indias pharma and healthcare sector recorded 71 deals amounting to USD 2.6 billion in Q1 2025, according to the Grant Thornton Bharat Pharma & Healthcare Dealtracker. While this marks a 5 per cent decline in deal volume and a 69 per cent drop in deal value compared to Q4 2024, the report notes continued investor interest. Mergers and acquisitions (M&A) accounted for 57 per cent of the total deal value, while private equity (PE) made up 59 per cent of the overall deal volume.

More Trending

article thumbnail

What’s being cut at NIH

PharmaVoice

A look at the government’s far-reaching rollback in research grants so far.

245
245
article thumbnail

FDA approves novel therapy for chronic skin condition

European Pharmaceutical Review

For the first time in over ten years, the US Food and Drug Administration (FDA) has approved a new targeted treatment for chronic spontaneous urticaria. Sanofi and Regeneron Pharmaceuticals collaborated to develop Dupixent (dupilumab). Under the FDA’s new authorisation, the therapy is indicated for individuals aged 12 years and over with the chronic inflammatory skin disease, who still experience symptoms despite taking histamine-1 (H1) antihistamine medication.

105
105
article thumbnail

New leadership role created at RPS as director for England sought

The Pharmacist

The Royal Pharmaceutical Society (RPS) is recruiting for a new director for England after previous postholder Dr James Davies left the role at the end of last year. Applicants for the 80,000-85,000 director for England role must be a pharmacist, an RPS member, and have experience or knowledge of more than one sector in pharmacy […] The post New leadership role created at RPS as director for England sought appeared first on The Pharmacist.

87
article thumbnail

Opinion: Short-term diet trials are designed to fail

STAT

Imagine a clinical trial with sedentary, overweight adults. One group is assigned to remain sedentary, the other to undergo intensive physical training with daily runs, calisthenics, and sports. After a week or two, the training group would probably feel sore and tired, and their endurance might be reduced. But we wouldn’t conclude that physical activity is bad for health.

360
360
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Can anything threaten Novo and Lilly’s obesity market dominance?

PharmaVoice

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

221
221
article thumbnail

Morepen Laboratories expands its domestic portfolio

Express Pharma

Morepen Laboratories has announced the launch of four new productsTicapen, UdoFix, LycoMore, and Acifix Raftin April 2025 for the Indian market. This follows the introduction of Empamore last month, furthering the companys stated goal to offer research-led pharmaceutical products across key therapeutic areas. These launches form part of Morepens broader strategy to enhance its finished dosages segment while leveraging its internal research and development (R&D) capabilities.

article thumbnail

Government seeks pharmacists' views to underpin first-ever men’s health strategy

The Pharmacist

The government has launched a call for evidence to support its Mens Health Strategy, which was announced last year and is the first of its kind. Health professionals are among those being asked for ideas and evidence to the unique challenges men face throughout their lives. The strategyis being developed to tackle stark inequalities in […] The post Government seeks pharmacists' views to underpin first-ever mens health strategy appeared first on The Pharmacist.

80
article thumbnail

Intensive lowering of blood pressure tied to lower dementia risk

STAT

High blood pressure earned its reputation as the silent killer by causing heart attacks, heart failure, and strokes. It’s also been a suspect in dementia. Some studies have hinted at a correlation between lower blood pressure and fewer dementia cases, but they were too small and too short to lend statistical significance to the link. It’s also been noted that people with untreated high blood pressure carry a 42% higher risk of developing dementia.

337
337
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

How a scrapped Pfizer drug became a winner for SpringWorks

PharmaVoice

SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

183
183
article thumbnail

Lupin receives US FDA approval for generic Tolvaptan Tablets

Express Pharma

Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. The approved product is bioequivalent to Jynarque Tablets of the same strengths, originally developed by Otsuka Pharmaceutical Company Lupin is the exclusive first-to-file applicant for this product, making it eligible for 180 days of generic drug exclusivity in the United States.

article thumbnail

Philippe Masset appointed to Vect-Horus board of directors

Pharmafile

Vect-Horus has announced the appointment of Philippe Masset to the companys board of directors. This contributes to a series of senior leadership appointments which are strategic for Vect-Horus growth. Masset is a senior banking executive with a wealth of experience in investment banking, environmental, social and governance (ESG) topics, sustainable finance, and AI.

76
article thumbnail

Public health leaders, distrustful of RFK Jr., stand up project to defend vaccines 

STAT

Some key public health figures are taking an extraordinary step to try to shore up U.S. vaccination policy, feared to be under threat from Health and Human Services Secretary Robert F. Kennedy Jr., a longtime vaccine critic. The “Vaccine Integrity Project,” which was publicly launched Thursday by the University of Minnesota’s Center for Infectious Disease Research and Policy, will be aimed at assessing the best ways for vaccine proponents to safeguard vaccination policy and

Vaccines 337
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

The Impact of Drug Patent Expiration: Financial Implications, Lifecycle Strategies, and Market Transformations

Drug Patent Watch

"Patent Expiration: The $1.4 Trillion Wake-Up Call for the Pharmaceutical Industry As the pharmaceutical landscape continues to shift, one thing is clear: the expiration of drug patents is no longer a footnote in the industry's financials. According to a recent analysis, the loss of exclusivity for top-selling medications will result in a staggering $1.4 trillion in lost revenue by 2025.

73
article thumbnail

Flagship’s latest venture reflects more than 25 years of leaping into the unknown

PharmaVoice

A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

163
163
article thumbnail

Reports Document FDA Review Delays: What Drugmakers Should Know Now

FDA Law Blog: Biosimilars

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a

article thumbnail

STAT+: No new autism registry, HHS says, walking back NIH director’s claim

STAT

The federal health department is not creating a new registry of Americans with autism, a Department of Health and Human Services official said in a written statement Thursday. Instead, the official said, HHS will launch a $50 million research effort to understand the causes of autism spectrum disorder and improve treatments. The announcement arrives two days after National Institutes of Health Director Jay Bhattacharya announced the intent to create such a registry at an all staff meeting, kicki

363
363
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Generic Drug Development: Avoid These Common Pitfalls

Drug Patent Watch

"Warning: Are You About to Fall into the Generic Drug Development Trap? As a seasoned pharma professional, I've seen it time and time again: promising generic drug candidates that fail to deliver due to avoidable pitfalls. Don't let this happen to you. Check out our latest blog post to learn how to avoid the most common mistakes in generic drug development: [link] From patent strategies to regulatory hurdles, we break down the key takeaways to help you navigate the complex landscape of gene

article thumbnail

Galapagos announces leadership changes amid planned company split

Pharmafile

Galapagos NV has announced key leadership changes as it prepares to separate into two independent entities. Henry Gosebruch has been appointed founding CEO of the newly created subsidiary, currently named SpinCo. The subsidiary, which will operate independently following the split, is funded by Galapagos. Gosebruch joins SpinCo with extensive experience in business development and mergers […] The post Galapagos announces leadership changes amid planned company split appeared first on Pharm

64
article thumbnail

ENTOD Pharmaceuticals receives CDSCO approval for paediatric myopia treatment

Express Pharma

ENTOD Pharmaceuticals has announced that it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for a new ophthalmic formulation designed to slow the progression of myopia in children aged 6 to 12 years. This marks the first global regulatory approval for this specific treatment strength in paediatric eye care.

59
article thumbnail

Opinion: The ‘yes, and’ approach to dementia care

STAT

When a person with dementia gets something fundamental wrong — the year it is, your relationship to them — it can be difficult to know what to do. Do you correct them and risk upsetting them? Is it a lie or unethical to go along with it? Ted Johnson, who chairs the Department of Family and Preventive Medicine at the Emory School of Medicine, says that playing along is not only OK; it’s often the best thing for both the patient and the caretaker.

264
264
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Almost five million Pharmacy First consultations delivered in first year

The Pharmacist

Almost five million Pharmacy First consultations were delivered in the first year of the service in England, official data has confirmed. The latest data from the NHS Business Services Authority (NHSBSA) shows that contractors in England submitted claims for 4,941,308 Pharmacy First consultations between February 2024 and January 2025. Of those, more than half (2,735,577) […] The post Almost five million Pharmacy First consultations delivered in first year appeared first on The Pharmacist.

59
article thumbnail

Smaller Pharmacies, Bigger Impact: Inside Manufacturers’ Specialty Networks in 2025

Drug Channels

Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , we explore how pharmaceutical manufacturers structure their specialty pharmacy networksand how smaller, independent pharmacies have emerged as dominant pl

article thumbnail

Dual immunotherapy for bowel cancer now available under NHS

Pharmafile

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), and recommended by the National Institute for Health and Care Excellence (NICE). It is now a treatment option via NHS-funded commissioning, marking a major milestone for treating patients with […] The post Dual immunotherapy for bowel cancer now available under NHS appeared first on Pharmafile.

66